IMCIVREE Drug Patent Profile

When do Imcivree patents expire, and what generic alternatives are available?

Imcivree is a drug marketed by Rhythm and is included in one NDA. There are three patents protecting this drug.

The generic ingredient in IMCIVREE is setmelanotide acetate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the setmelanotide acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Imcivree

Imcivree was eligible for patent challenges on November 25, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 4, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for IMCIVREE

US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	19
Clinical Trials:	1
Drug Prices:	Drug price information for IMCIVREE
What excipients (inactive ingredients) are in IMCIVREE?	IMCIVREE excipients list
DailyMed Link:	IMCIVREE at DailyMed

See drug prices for IMCIVREE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IMCIVREE

NDA:

213793

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IMCIVREE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rhythm Pharmaceuticals, Inc.	Phase 3

See all IMCIVREE clinical trials

Pharmacology for IMCIVREE

Drug Class	Melanocortin 4 Receptor Agonist
Mechanism of Action	Melanocortin 4 Receptor Agonists

US Patents and Regulatory Information for IMCIVREE

IMCIVREE is protected by three US patents and six FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rhythm	IMCIVREE	setmelanotide acetate	SOLUTION;SUBCUTANEOUS	213793-001	Nov 25, 2020		RX	Yes	Yes			Y
Rhythm	IMCIVREE	setmelanotide acetate	SOLUTION;SUBCUTANEOUS	213793-001	Nov 25, 2020		RX	Yes	Yes
Rhythm	IMCIVREE	setmelanotide acetate	SOLUTION;SUBCUTANEOUS	213793-001	Nov 25, 2020		RX	Yes	Yes
Rhythm	IMCIVREE	setmelanotide acetate	SOLUTION;SUBCUTANEOUS	213793-001	Nov 25, 2020		RX	Yes	Yes
Rhythm	IMCIVREE	setmelanotide acetate	SOLUTION;SUBCUTANEOUS	213793-001	Nov 25, 2020		RX	Yes	Yes			Y	Y
Rhythm	IMCIVREE	setmelanotide acetate	SOLUTION;SUBCUTANEOUS	213793-001	Nov 25, 2020		RX	Yes	Yes			Y	Y

International Patents for IMCIVREE

When does loss-of-exclusivity occur for IMCIVREE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

France

Hong Kong

Israel

Japan

Netherlands

Norway

Poland

Portugal

Russian Federation

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IMCIVREE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014228460
Australia	2019200101
Australia	2021202699
Australia	2023204625
Australia	2025213562
Brazil	112015023409

Supplementary Protection Certificates for IMCIVREE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2236151	301150	Netherlands		PRODUCT NAME: SETMELANOTIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/21/1564 20210719
2970389	301149	Netherlands		PRODUCT NAME: SETMELANOTIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/21/1564 20210719
2970389	CA 2021 00054	Denmark		PRODUCT NAME: SETMELANOTID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1564 20210719
2970389	2021C/551	Belgium		PRODUCT NAME: SETMELANOTIDE, ALSMEDE DOOR HET BASISOCTROOI BESCHERMDE, THERAPEUTISCH EQUIVALENTE AFGELEIDEN ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1564 20210719
2236151	CA 2021 00053	Denmark		PRODUCT NAME: SETMELANOTID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1564 20210719
2236151	2021C/557	Belgium		PRODUCT NAME: SETMELANOTIDE, ALSMEDE DOOR HET BASISOCTROOI BESCHERMDE, THERAPEUTISCH EQUIVALENTE AFGELEIDEN ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1564 20210719

Last updated: July 29, 2026

IMCIVREE (setmelanotide) market dynamics and financial trajectory: sales drivers, pricing pressure, payer coverage, and exclusivity risk

Executive summary: IMCIVREE (setmelanotide) has a narrow but growing addressable population across rare genetic obesity (POMC, PCSK1, LEPR deficiencies). Near-term revenue is driven by (1) increasing diagnosis rates and referral flows to specialized obesity/Genetic clinics, (2) specialty pharmacy distribution and adherence to daily dosing, and (3) payer acceptance tied to biomarker-confirmed eligibility. Medium-term risk is higher from (1) competitive pipeline entrants in melanocortin-pathway modulation, (2) payer attempts to re-negotiate rebates as budget impact becomes measurable, and (3) future patent and exclusivity cliffs that can enable generic or follow-on substitutes, depending on claim scope and regulatory exclusivity status. IMCIVREE’s financial trajectory is best modeled as “small base, payer-restricted, high retention once started,” with revenue volatility linked to coverage decisions, prior authorization outcomes, and the mix of patients by genotype and clinical response.

---

What is IMCIVREE (setmelanotide) and which patient population drives revenue?

Short answer: IMCIVREE targets rare monogenic obesity caused by impaired leptin-melanocortin signaling, with eligibility anchored to genetic confirmation.

Indications and commercial eligibility

Setmelanotide is marketed for:

• POMC deficiency
• PCSK1 deficiency
• LEPR deficiency
  (Clinical label descriptions are consistent across US labeling; payer eligibility typically requires genetic testing documentation and clinical criteria.)

Revenue implication: Sales are constrained by (a) prevalence of these rare genetic etiologies, (b) diagnostic testing adoption, and (c) payer willingness to cover high-cost, daily therapy for patients who meet label criteria.

Reimbursement gatekeeping: what payers typically require

Commercial and government payers commonly require:

• Documented genetic variant consistent with an approved indication
• Prior authorization with specialist support (endocrinology/genetics/obesity centers)
• Evidence of continued need (response monitoring)
• Use through specialty pharmacy channels

Market dynamic: Because the addressable population is small, coverage denials and delays can have outsized impact on month-to-month patient starts, producing lumpy sales rather than smooth growth.

---

How do market dynamics shape IMCIVREE sales growth: diagnosis rates, centers of excellence, and specialty pharmacy economics?

Diagnosis and referral economics

For rare diseases, revenue growth often tracks:

• Increased genetic testing throughput for obesity cohorts
• Referral concentration in tertiary centers
• Programmatic patient support that converts “identified” to “treated”

Impact on trajectory: Each incremental center or testing pathway can add patients faster than the broader population, so sales growth can accelerate when referral networks broaden.

Specialty pharmacy model

IMCIVREE’s commercial mechanics are typical of high-cost orphan drugs:

• Dispensed through specialty distributors/pharmacies
• Daily administration supports ongoing demand rather than one-time procedures
• Inventory and logistics are optimized through specialty channels

Pricing and rebate effect: Specialty pharmacy revenue recognition is influenced by net price after rebates, chargebacks, and patient assistance use. Even when gross list price stays stable, net realized price can move with payer contracting.

---

What is the pricing and payer coverage landscape for IMCIVREE (setmelanotide) in the US?

Short answer: Access hinges on prior authorization, clinical criteria, and negotiated rebate rates; net pricing is usually materially below list price for commercial plans.

Key payer forces

• Budget impact: Even with low prevalence, per-patient monthly cost can drive payer scrutiny.
• Comparative value arguments: Payers evaluate outcomes such as weight change, hunger/food-seeking behavior, and functional improvements within labeled cohorts.
• Contracting sophistication: Larger payers seek outcomes-aligned language and tighter documentation requirements.

Government payer dynamics

Medicaid and Medicare Part D access patterns typically involve:

• Formulary designations or prior authorization requirements
• Lower willingness to absorb net cost without strict medical necessity documentation
• Faster uptake when criteria are standardized and genetics confirmation processes are established

---

When does IMCIVREE lose exclusivity, and what does that mean for generic or follow-on risk?

Short answer: The main market risk is timing of patent term and regulatory exclusivity periods that limit direct competition.

Exclusivity map: what drives “date-to-competition”

For prescription small molecules, competition timing typically reflects:

• Patent expiration (composition-of-matter, formulation, method-of-use)
• Regulatory exclusivity (orphan drug exclusivity where applicable)
• Any patent settlements that resolve Paragraph IV-type threats

Commercial modeling of risk

• If exclusivity remains intact, follow-on competition is more likely to be “better contracting” (rebate changes, step edits to prior auth) rather than new chemical entity entry.
• If key claims expire, entry can come via ANDA for small molecule generics or via follow-on products (depending on claim coverage and formulation method patents).

Practical market impact: The closer the date-to-expiration, the more payers move toward “hard formulary management,” which can lower net realized price even before generic entry.

---

How many patents cover IMCIVREE and which claim types typically matter most for competition?

Short answer: For branded orphan drugs like IMCIVREE, the patent estate usually includes composition, use, and formulation or dosing regimens, with method-of-use and dosing patents often shaping entry timing.

Claim-type relevance for market exclusivity

Patent barriers that matter most for competitive entry typically include:

• Composition-of-matter claims on setmelanotide
• Method-of-use claims linked to genotype-defined obesity
• Formulation and delivery system claims (if present)
• Dosing regimen claims (timing, titration, patient selection)

Why this matters financially

• If method-of-use claims remain active, generics may be blocked for the labeled indication unless “skinny label” design is possible.
• If composition claims expire first, generics may still launch for off-label use only, depending on label protection and enforcement strategy.

---

What patent litigation or Paragraph IV challenges affect IMCIVREE market entry risk?

Short answer: The financial trajectory depends on whether competitors file challenging applications and whether settlements delay launch.

How litigation changes market dynamics

• Paragraph IV challenges can trigger delayed exclusivity for the challenger if settlement is reached.
• Court rulings can compress or extend time-to-launch.
• Settlements can “lock in” branded revenue by extending effective competition delays.

Commercial implication: Even without final generic launches, litigation headlines often lead payers to preemptively tighten criteria and negotiate for higher rebates in anticipation of entry.

---

How does IMCIVREE compare with other rare-obesity or melanocortin pathway therapies on competitive intensity?

Short answer: IMCIVREE has a specialized, genotype-defined niche, so direct competitors must either target the same genetic cohorts or displace setmelanotide through broader mechanisms.

Competitive comparison dimensions

• Target population overlap: POMC/PCSK1/LEPR overlap is specific; partial overlap supports incremental competition risk.
• Dosing simplicity: Once-daily regimens support adherence.
• Clinical endpoints: Payers prioritize demonstrable clinically meaningful weight and hunger reduction.
• Coverage behavior: Competitors can gain share if they reduce documentation burden or show stronger responder rates.

Market share mechanics

Because the eligible pool is limited, competitive share shifts tend to show up as:

• Slower patient starts for IMCIVREE
• Switching among treated patients where a second option becomes preferred
• Increased payer utilization management

---

What is the FDA regulatory status of IMCIVREE, and how does it affect commercial timing and competition?

Short answer: FDA approval and post-approval label stability affect market trust and payer willingness to cover.

Regulatory factors that shape adoption

• Label clarity tied to genetic diagnostic criteria
• Any post-marketing updates to eligibility or clinical endpoints
• REMS or special handling requirements (if any)
• Manufacturing continuity and supply reliability

Financial effect: Supply constraints can cap sales growth; stable supply supports consistent patient onboarding and retention.

---

How strong is IMCIVREE’s commercial trajectory: what indicators should be used to forecast net sales?

Short answer: For a rare orphan drug, the best forecasting inputs are patient starts, retention, and net price rather than broad macro demand.

Key KPI stack for revenue modeling

1. Patient starts per quarter (new initiations)
2. Persistence/retention (continued use under coverage and clinical response rules)
3. Net price per treated patient (list minus rebates, chargebacks, and assistance impact)
4. Mix by genotype and response status (responders may meet continuation criteria better)
5. Geographic distribution and payer mix shift
6. Specialty pharmacy fill rates and time-to-first-fill

Why these KPIs matter

• Starts are directly tied to diagnosis volume and referral workflows.
• Retention determines revenue durability because daily dosing creates recurring revenue.
• Net price is the most sensitive variable as payers renegotiate for rare high-cost products.

---

What are the main risks to IMCIVREE’s revenue growth: payer renegotiation, uptake saturation, and exclusivity erosion?

Payer renegotiation

• Increased rebate pressure as total covered lives increase
• Tougher prior authorization criteria for continuation
• Utilization management edits near generic or follow-on entry windows

Uptake saturation

• Once major centers are fully recruited, incremental starts depend on new referrals and broader genetic testing adoption.
• If patient identification slows, growth transitions from rapid expansion to slower growth.

Exclusivity erosion

• Patent expiration and orphan exclusivity changes can reprice the therapy risk premium.
• Even if a generic cannot fully replace labeled use, “skinny label” or restrictive competition can pressure net pricing.

---

Key Takeaways

• IMCIVREE’s financial trajectory is driven by a small, genotype-defined population, making patient identification, coverage approvals, and retention the dominant growth levers.
• Market dynamics show high sensitivity to payer contracting, prior authorization criteria, and specialty pharmacy onboarding efficiency, leading to lumpy starts and net price variability.
• The primary medium-term revenue risk is exclusivity and patent estate erosion, which can trigger earlier payer hardening and post-expiration competition, even before actual generic launch.
• Revenue forecasting should center on quarterly patient starts, persistence, payer mix, and net realized pricing rather than broad market demand indicators.

---

FAQs

What drives changes in IMCIVREE net sales more than list price?

Net realized price, including rebates, chargebacks, and patient assistance mix, plus quarterly patient start volume and persistence.

Do payers restrict IMCIVREE coverage by genotype-specific response?

Coverage and continuation policies often tie eligibility to genetic confirmation and may include response-based continuation review.

How does specialty pharmacy affect time-to-treatment for IMCIVREE?

Specialty distribution creates operational timelines that can slow or accelerate time-to-first-fill, directly impacting quarterly patient starts.

What competitive event would most likely pressure IMCIVREE revenue before generic entry?

A credible pipeline entrant that targets overlapping rare obesity cohorts, or payer renegotiations initiated ahead of expected exclusivity or patent cliffs.

What is the best indicator of IMCIVREE demand durability?

Persistence over time, supported by continued coverage approvals and clinically meaningful response in labeled cohorts.

---

References (APA)

1. FDA. IMCIVREE (setmelanotide) Prescribing Information. US Food and Drug Administration.
2. FDA Orange Book. IMCIVREE (setmelanotide) entries. US Food and Drug Administration.
3. FDA. Drug Approval Package for IMCIVREE (setmelanotide). US Food and Drug Administration.
4. Centers for Medicare & Medicaid Services (CMS). National Drug Code and coverage policies (where applicable). CMS.